Prs65 Adherence and Persistence to Roflumilast Among Adult Patients With Chronic Obstructive Pulmonary Disease

Abstract

and 95.5% respectively. Simplicity was high among all the parameters (96.8%) in the scale content validity index(S-CVI). The internal consistency of the questionnaire measured using Cronbach's alpha was found 0.9. A total of 46 patients completed, 5 were drop out. Asthma (21.95%) and COPD patients (48.75%) group majority were male patients. Majority of asthma patient (34.14%) were non alcoholic and non smoker, whereas majority of COPD patients were (39.02%) were alcoholic and smoker. The questionnaire analysis was able to measure the change in medication adherence. Conclusions: The prepared medication adherence questionnaire was capable to assess the change in medication adherence. COPD patient were having better adherence than asthma patients.

PDE4 inhibitors: potential protective effects in inflammation and vascular diseases

“…It gained approval for treating severe COPD and asthma in 2010 and 2011, respectively. Although roflumilast demonstrates improved performance in clinical trials compared to rolipram, gastrointestinal adverse reactions still occur 9.5% of cases, manifesting as diarrhea, nausea, headache, weight loss, urinary tract infections, and psychiatric disorders ( Asfaw, 2020 ). Considering the relative equilibrium between efficacy and safety, along with proper dosing strategy and comprehensive assessment of drug safety, roflumilast undeniably confers greater benefits than risks to patients.…”